How long should apixaban (Eliquis) be discontinued prior to spinal cord stimulator implantation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Apixaban (Eliquis) Discontinuation Before Spinal Cord Stimulator Surgery

For spinal cord stimulator implantation, discontinue apixaban (Eliquis) at least 48 hours (2 days) prior to the procedure, though 72 hours (3 days) is preferred for this high-risk neuraxial intervention.

Rationale and Evidence Hierarchy

Spinal cord stimulator placement involves epidural access and catheter placement, which carries very high hemorrhagic risk due to the potential for epidural hematoma and permanent neurological injury. This procedure falls into the highest risk category for bleeding complications.

Primary Guidance from FDA Label and Guidelines

The FDA label for Eliquis explicitly states discontinuation at least 48 hours prior to procedures with moderate or high risk of bleeding 1. However, this represents the minimum threshold for general surgical procedures.

For neuraxial procedures specifically, more conservative timing is warranted:

  • The 2017 French Working Group on Perioperative Hemostasis (GIHP) guidelines classify neuraxial anesthesia/puncture as very high hemorrhagic risk requiring up to 5 days interruption for direct oral anticoagulants when renal function is normal 2

  • The 2013 UK Association of Anaesthetists guidelines recommend 24-48 hours for apixaban prophylaxis doses before neuraxial blockade 3

  • The FDA label specifically warns that indwelling epidural catheters should not be removed earlier than 24 hours after the last apixaban dose, and the next dose should not be given earlier than 5 hours after catheter removal 1

Practical Algorithm for Timing

Base your discontinuation timing on renal function:

  1. Normal renal function (CrCl >80 mL/min): Stop apixaban 48-72 hours before surgery

    • 48 hours minimum per FDA guidance 1
    • 72 hours preferred for neuraxial procedures per French guidelines 2
  2. Mild renal impairment (CrCl 50-80 mL/min): Stop apixaban 72 hours before surgery 2

  3. Moderate renal impairment (CrCl 30-50 mL/min): Stop apixaban 96 hours (4 days) before surgery 2

  4. Severe renal impairment (CrCl <30 mL/min): Consider up to 5 days discontinuation and potentially measure anti-Xa levels 2

Additional Risk Factors Requiring Longer Discontinuation

Extend the discontinuation period if the patient has:

  • Age ≥80 years (apixaban clearance is reduced) 2
  • Concomitant P-glycoprotein inhibitors (verapamil, amiodarone, clarithromycin) 2
  • Body weight <60 kg 2

Supporting Research Evidence

Recent real-world data confirms safety of 48-hour discontinuation: A 2022 prospective study found that 94% of patients achieved clinically insignificant apixaban levels (≤30 ng/mL) with median discontinuation of 76 hours 4. However, one patient with only 59 hours discontinuation had levels >30 ng/mL, reinforcing the need for adequate timing.

A 2024 case report demonstrated that elderly patients with renal dysfunction can have detectable apixaban levels for >10 days after the last dose, delaying necessary surgery 5. This underscores the importance of considering renal function.

Critical Warnings

The French guidelines explicitly state: "The entire group strongly recommends not performing spinal or epidural anesthesia or deep-block techniques in patients with a possible DOA concentration (insufficient discontinuation time), in particular in patients on dabigatban over 80 years of age or in renal failure" 2. This applies equally to apixaban.

Common Pitfalls to Avoid

  1. Do not rely on standard 48-hour timing in elderly or renally impaired patients - these populations require longer discontinuation periods
  2. Do not perform the procedure if there is uncertainty about the last dose timing - verify with the patient and pharmacy records
  3. Do not assume bridging anticoagulation is needed - it is generally not required and increases bleeding risk 1
  4. Consider anti-Xa level measurement if there is concern about residual anticoagulation, particularly in high-risk patients 2, 5

Resumption After Surgery

Resume apixaban at least 24 hours after epidural catheter removal and only after adequate hemostasis is established 1. For permanent spinal cord stimulator trials where the epidural space is not re-accessed, standard postoperative timing applies (typically 24-48 hours post-procedure depending on bleeding risk) 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.